iCare ILLUME for screening

Part of iCare Screening Solution that helps detect the early signs of diabetic retinopathy (DR), age-related macular degeneration (AMD), and glaucoma (GLC) using artificial intelligence (AI)

Key features

Efficient screening for DR, AMD, and glaucoma, enabling early intervention
AI automatically detects early signs of disease and classifies the results according to severity
Patient report with useful heatmaps indicate areas with possible abnormalities
Unique confocal technology of the iCare DRSplus fundus imaging system enables screening of all patients, including those with ocular media opacities
Faster and more efficient screenings that enable timely help to patients who need it

Description

Fast and effortless screening in all care settings using artificial intelligence

iCare Screening Solution is a unique combination of specialized software iCare ILLUME using artificial intelligence iCare RETCAD for image analysis and TrueColor Confocal fundus imaging system iCare DRSplus for retinal imaging. Key advantages include a fully automated workflow, high-quality detailed images without dilation, and ILLUME Connect — an option to also share referrals outside of the source organization.

AI reliably and efficiently reviews images — saving valuable time, enabling early intervention, and helping to optimize workflows. For the first time, screening is possible for all patients, including those with ocular media opacities such as cataracts and vitreous cloudiness.

Swift, fully automated operations

The iCare DRSplus fundus imaging system is intuitive and requires minimal staff training.

High-quality images are automatically and securely stored and forwarded for processing by AI.

The report is instantly available and can be discussed with the patient during the same visit.

AI instantly detects early signs of retinal pathology

Artificial intelligence provides efficient processing for higher throughput and reliable results that match the level of a professional human grader. AI detects early signs instantly and classifies the results according to severity. The results available in a downloadable report.

Fully automated operations offer significant timesaving

iCare ILLUME saves time and speeds up your workflow, thanks to a fully automated process. The iCare DRSplus fundus imaging system is intuitive, easy to use, and requires minimal staff training. There is no need for dilation, as DRSplus can take images through pupils down to a width of 2,5mm. After imaging, the report is instantly available for viewing and discussion with the patient.

iCare DRSplus product page

Enabling digital screening pathways and ensuring data security and privacy

With the iCare ILLUME Connect referrals can also be shared outside your organization to increase patient care compliance. At iCare, data security and privacy meet the highest standards. Screening results can be stored in most widely used electronic health record systems. This improves communication between caregivers.

A case of a patient with undiagnosed diabetic retinopathy

Early detection of retinopathy and urgent referral to an ophthalmologist for further diagnostics and treatment provide a real opportunity to halt the progression of diabetic retinopathy and prevent vision loss. Download the patient case to learn more about the benefits of using AI-powered image analysis in screening for DR.

Download the case

Diabetic retinopathy screening with confocal fundus camera and artificial intelligence – assisted grading

The recent study shows that iCare DRSplus paired with RetCAD* represents a reliable DR screening solution in a real-world setting. The high sensitivity of the system ensures that almost all patients requiring medical attention for DR are referred to an ophthalmologist for further evaluation. Read the abstract of Dr Piatti’s study “Diabetic retinopathy screening with confocal fundus camera and artificial intelligence – assisted grading”

*The product has now been renamed iCare RECAD and has been cleared in Europe by CENTERVUE S.P.A. as the legal manufacturer,
without any changes to its algorithm or performance metrics.

iCare ILLUME offers versatile business benefits

With iCare ILLUME, healthcare professionals can experience a significant reduction in workload, while maintaining high accuracy, thanks to improved detection, fast and consistent reports, and an easy-to-use interface.
ILLUME is an ideal solution to optimize workflow, streamline processes, scale up screening programs, ensure continuity of care in primary care, and ultimately, save costs.

High-quality images meet the requirements of AI on the first take

Excellent image quality is the prerequisite for reliable and efficient screening. iCare’s TrueColor Confocal Technology presents accurate documentation of the retina in detail-rich images which seldom need to be retaken for analysis by AI. iCare DRSplus can also capture high-quality images through ocular media opacities (cataract, vitreous) – enabling the screening of diabetic retinopathy suspects already suffering from these.

Testimonials

On the motivation behind adopting AI screening:

“We see AI as a powerful tool to support both our customers and our team—offering fast, reliable insights that make early detection part of everyday eye care.”

Daniela Steinkämper, Viehoff Gruppe, Münster, Germany
The iCare screening solution for diabetic retinopathy has truly impressed me. I am fully convinced of its effectiveness and reliability.

Prof. Nina Hautala, Oulu University Hospital, Oulu, Finland
Using iCare Screening Solution, we detect the patient’s retinopathy early and refer them for urgent care. This timely intervention helps prevent further vision loss.

Dr. Wojciech Matuszewski, Clinic of Endocrinology, Diabetology and Internal Medicine, WSS, UWM Olsztyn, Poland

All testimonials

Interested?

Local qualified iCare distributors are ready to help you with all matters related to iCare products and services.
Contact us
Product materials

Get support materials for your iCare products by filling in the form.
Material request

All articles

PLEASE NOTE: Not all products, services or offers referenced are approved or offered in every market, and approved labelling and instructions may vary from one country to another. Product specifications are subject to change in design and scope of delivery and as a result of ongoing technical developments.